Alopecia Areata-like Hair Loss Accompanying Toxic Epidermal Necrolysis. 2018

Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyush, 807-8555, Japan, Japan.

UI MeSH Term Description Entries
D007156 Immunologic Memory The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus. Immune Memory,Immunological Memory,Memory, Immunologic,Immune Memories,Immunologic Memories,Immunological Memories,Memory, Immune,Memory, Immunological
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000506 Alopecia Areata Loss of scalp and body hair involving microscopically inflammatory patchy areas. Alopecia Circumscripta
D013256 Steroids A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed) Steroid,Catatoxic Steroids,Steroids, Catatoxic
D013262 Stevens-Johnson Syndrome Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis. Drug-Induced Stevens Johnson Syndrome,Drug-Induced Stevens-Johnson Syndrome,Epidermal Necrolysis, Toxic,Lyell's Syndrome,Mycoplasma-Induced Stevens Johnson Syndrome,Mycoplasma-Induced Stevens-Johnson Syndrome,Nonstaphylococcal Scalded Skin Syndrome,Scalded Skin Syndrome, Nonstaphylococcal,Stevens Johnson Syndrome Toxic Epidermal Necrolysis,Stevens Johnson Syndrome Toxic Epidermal Necrolysis Spectrum,Stevens-Johnson Syndrome Toxic Epidermal Necrolysis,Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum,Toxic Epidermal Necrolysis,Toxic Epidermal Necrolysis Stevens Johnson Syndrome,Toxic Epidermal Necrolysis Stevens Johnson Syndrome Spectrum,Toxic Epidermal Necrolysis Stevens-Johnson Syndrome,Toxic Epidermal Necrolysis Stevens-Johnson Syndrome Spectrum,Drug Induced Stevens Johnson Syndrome,Drug-Induced Stevens-Johnson Syndromes,Epidermal Necrolyses, Toxic,Lyell Syndrome,Lyell's Syndromes,Mycoplasma Induced Stevens Johnson Syndrome,Necrolyses, Toxic Epidermal,Necrolysis, Toxic Epidermal,Stevens Johnson Syndrome,Stevens-Johnson Syndrome, Drug-Induced,Stevens-Johnson Syndrome, Mycoplasma-Induced,Stevens-Johnson Syndromes, Drug-Induced,Syndrome, Lyell's,Syndrome, Mycoplasma-Induced Stevens-Johnson,Syndromes, Lyell's,Toxic Epidermal Necrolyses
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
October 2021, Clinical and experimental dermatology,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
January 2004, European journal of dermatology : EJD,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
September 1984, Ugeskrift for laeger,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
September 1997, The Journal of investigative dermatology,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
June 2022, JAMA,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
August 1970, JAMA,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
September 1980, The Medical clinics of North America,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
July 1993, Ugeskrift for laeger,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
January 1967, Canadian Medical Association journal,
Emi Mashima, and Yu Sawada, and Akiha Inoue, and Natsuko Saito-Sasaki, and Takashi Yamaguchi, and Haruna Yoshioka, and Shun Ohmori, and Sanehito Haruyama, and Manabu Yoshioka, and Etsuko Okada, and Motonobu Nakamura
March 1976, Ugeskrift for laeger,
Copied contents to your clipboard!